Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling.

Hofland T, Endstra S, Gomes CKP, de Boer R, de Weerdt I, Bobkov V, Riedl JA, Heukers R, Smit MJ, Eldering E, Levin MD, Kater AP, Tonino SH.

Hemasphere. 2019 Oct 30;3(6):e308. doi: 10.1097/HS9.0000000000000308. eCollection 2019 Dec.

2.

Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.

Ruchlemer R, Ben-Ami R, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino SH, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill B, Mulligan SP, Nijland M, Herishanu Y, Benjamini O, Tadmor T, Okamoto K, Arthurs B, Gottesman B, Kater AP, Talha M, Eichhorst B, Korem M, Bogot N, De Boer F, Rowe JM, Lachish T.

Mycoses. 2019 Dec;62(12):1140-1147. doi: 10.1111/myc.13001. Epub 2019 Oct 22.

PMID:
31520441
3.

Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.

Hofland T, de Weerdt I, Ter Burg H, de Boer R, Tannheimer S, Tonino SH, Kater AP, Eldering E.

J Immunol. 2019 Oct 15;203(8):2100-2109. doi: 10.4049/jimmunol.1900321. Epub 2019 Sep 11.

PMID:
31511358
4.

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

de Weerdt I, Hofland T, de Boer R, Dobber JA, Dubois J, van Nieuwenhuize D, Mobasher M, de Boer F, Hoogendoorn M, Velders GA, van der Klift M, Remmerswaal EBM, Bemelman FJ, Niemann CU, Kersting S, Levin MD, Eldering E, Tonino SH, Kater AP.

Blood Adv. 2019 Sep 10;3(17):2642-2652. doi: 10.1182/bloodadvances.2019000360.

5.

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia.

Hofland T, Eldering E, Kater AP, Tonino SH.

Int J Mol Sci. 2019 Sep 3;20(17). pii: E4315. doi: 10.3390/ijms20174315. Review.

6.

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.

van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW.

Blood. 2019 Jul 4;134(1):44-58. doi: 10.1182/blood.2018885863. Epub 2019 May 10.

PMID:
31076448
7.

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.

Kater AP, Kersting S, van Norden Y, Dubois J, Dobber JA, Mellink CH, Evers LM, Croon-de Boer F, Schreurs J, van der Spek E, Visser H, Idink C, Wittebol S, Hoogendoorn M, Tonino SH, Mobasher M, Levin MD; HOVON CLL study group.

Blood Adv. 2018 Dec 26;2(24):3566-3571. doi: 10.1182/bloodadvances.2018019422.

8.

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ.

Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31. No abstract available.

9.

Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.

de Weerdt I, Hofland T, Lameris R, Endstra S, Jongejan A, Moerland PD, de Bruin RCG, Remmerswaal EBM, Ten Berge IJM, Liu N, van der Stelt M, Faber LM, Levin MD, Eldering E, Tonino SH, de Gruijl TD, van der Vliet HJ, Kater AP.

Blood. 2018 Nov 22;132(21):2260-2272. doi: 10.1182/blood-2017-12-822569. Epub 2018 Sep 13. Erratum in: Blood. 2019 Oct 10;134(15):1271-1272.

PMID:
30213872
10.

Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations.

De Back TR, Kater AP, Tonino SH.

Expert Rev Hematol. 2018 Aug;11(8):613-624. doi: 10.1080/17474086.2018.1489720. Epub 2018 Jul 14. Review.

PMID:
29923432
11.

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.

Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, Gao J, Dreiling L, Xin Y, Doorduijn JK, Kersten MJ; HOVON Lunenburg Lymphoma Phase I/II Consortium.

Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x. No abstract available.

12.

Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.

Tonino SH, Mulkens CE, van Laar J, Derks IA, Suo G, Croon-de Boer F, van Oers MH, Eldering E, Wang JY, Kater AP.

Leuk Lymphoma. 2015;56(8):2439-47. doi: 10.3109/10428194.2014.996751. Epub 2015 Jan 21.

13.

How does lenalidomide target the chronic lymphocytic leukemia microenvironment?

Kater AP, Tonino SH, Egle A, Ramsay AG.

Blood. 2014 Oct 2;124(14):2184-9. doi: 10.1182/blood-2014-05-578286. Epub 2014 Aug 26. Review.

PMID:
25161268
14.

CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia.

te Raa GD, Pascutti MF, García-Vallejo JJ, Reinen E, Remmerswaal EB, ten Berge IJ, van Lier RA, Eldering E, van Oers MH, Tonino SH, Kater AP.

Blood. 2014 Jan 30;123(5):717-24. doi: 10.1182/blood-2013-08-518183. Epub 2013 Nov 18.

PMID:
24246502
15.

Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.

Kater AP, Spiering M, Liu RD, Doreen Te Raa G, Slinger E, Tonino SH, Beckers MM, Daenen S, Doorduijn JK, Lankheet NA, Luijks DM, Eldering E, van Oers MH.

Leuk Res. 2014 Jan;38(1):34-41. doi: 10.1016/j.leukres.2013.10.004. Epub 2013 Oct 28.

PMID:
24238639
16.

Chest pain in sickle cell disease.

Tonino SH, Nur E, Otten HM, Wykrzykowska JJ, Hoekstra JB, Biemond BJ.

Neth J Med. 2013 Jun;71(5):265-9.

17.

Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis.

te Raa GD, Tonino SH, Remmerswaal EB, van Houte AJ, Koene HR, van Oers MH, Kater AP.

Leuk Lymphoma. 2012 Nov;53(11):2321-5. doi: 10.3109/10428194.2012.698277. Epub 2012 Aug 25.

PMID:
22646856
18.

Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia.

Tonino SH, van de Berg PJ, Yong SL, ten Berge IJ, Kersten MJ, van Lier RA, van Oers MH, Kater AP.

Leuk Lymphoma. 2012 Sep;53(9):1785-94. doi: 10.3109/10428194.2012.673224. Epub 2012 Apr 19.

PMID:
22397719
19.

Intracerebral infiltration as the unique cause of the clinical presentation of chronic lymphocytic leukemia/small lymphocytic leukemia.

Tonino SH, Rijssenbeek AL, Oud ME, Pals ST, van Oers MH, Kater AP.

J Clin Oncol. 2011 Dec 1;29(34):e837-9. doi: 10.1200/JCO.2011.37.5055. Epub 2011 Oct 24. No abstract available.

PMID:
22025138
20.

ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.

Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, Kater AP.

Oncogene. 2011 Feb 10;30(6):701-13. doi: 10.1038/onc.2010.441. Epub 2010 Oct 11.

21.

Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.

Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP, van Lier RA, van Oers MH, Eldering E.

Oncogene. 2010 Sep 9;29(36):5071-82. doi: 10.1038/onc.2010.248. Epub 2010 Jun 28.

PMID:
20581863
22.

Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study.

Kater AP, Tonino SH.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10 Suppl 1:S34-41. doi: 10.3816/CLML.2010.s.005. Review.

PMID:
20529806
23.

R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia.

Tonino SH, van Gelder M, Eldering E, van Oers MH, Kater AP.

Leukemia. 2010 Mar;24(3):652-4. doi: 10.1038/leu.2009.240. Epub 2009 Dec 3. No abstract available.

PMID:
19956201
24.

Characterisation of Neisseria meningitidis C strains causing two clusters in the north of Italy in 2007 and 2008.

Fazio C, Neri A, Tonino S, Carannante A, Caporali MG, Salmaso S, Mastrantonio P, Stefanelli P.

Euro Surveill. 2009 Apr 23;14(16). pii: 19179.

25.

No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia.

Tonino SH, Spijker R, Luijks DM, van Oers MH, Kater AP.

Blood. 2008 Aug 1;112(3):840-3. doi: 10.1182/blood-2008-03-144576. Epub 2008 Jun 2.

PMID:
18519815
26.

Bench-to-bedside review: preventive measures for contrast-induced nephropathy in critically ill patients.

van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ.

Crit Care. 2005 Aug;9(4):361-70. Epub 2005 Jan 7. Review.

Supplemental Content

Loading ...
Support Center